Hornick R B, DuPont H L, Levine M M, Gilman R H, Woodward W E, Snyder M J, Woodward T E
Dev Biol Stand. 1976;33:89-92.
A live oral attenuated vaccine, lacking the enzyme epimerase, has been given with complete safety to 173 men. Two preparations of the vaccine, one with and one without galactose in the initial culture media, led to somewhat differing results. Vaccine A, prepared with galactose, was more readily identified in the stool specimens of its recipients and was more likely to provoke an O antibody response than was vaccine B. Furthermore, the clinical protection from typhoid fever was significant in the vaccine A group, whereas not so with the vaccine B counterpart. The protection afforded by vaccine A exceeds that of any of our previous candidate strains. It is perhaps not presumptuous to imagine that such a vaccine would be equally effective in an area endemic for typhoid fever, where the vaccine might act as a booster effect in a previously exposed population. Remaining questions to be answered include the duration of the protection, and the efficacy of a lyophilized preparation.
一种缺乏表异构酶的减毒活口服疫苗已在173名男性身上安全接种。该疫苗有两种制剂，一种在初始培养基中添加了半乳糖，另一种未添加，结果略有不同。在初始培养基中添加半乳糖制备的疫苗A，在其接种者的粪便样本中更容易被识别，并且比疫苗B更有可能引发O抗体反应。此外，疫苗A组对伤寒热的临床保护作用显著，而疫苗B组则不然。疫苗A提供的保护作用超过了我们之前的任何候选菌株。也许可以设想，这种疫苗在伤寒热流行地区同样有效，在该地区，疫苗可能会对先前接触过的人群起到增强作用。有待回答的其他问题包括保护作用的持续时间以及冻干制剂的效力。
